Renale denervatie verbetert leververvetting bij hypertensieve patiënten met metabool syndroom

BACKGROUND:Sympathetic overactivity is associated with hepatic steatosis. Renal denervation (RDN) is an approved treatment for uncontrolled hypertension through sympathetic modulation; however, its hepatic effects are unknown. This study aimed to assess the effects of RDN on noninvasive tests for hepatic steatosis.METHODS:This single-center study included patients with uncontrolled hypertension and cardiometabolic comorbidities undergoing RDN (n=32) or a sham procedure (n=10). Noninvasive tests for hepatic steatosis, including the hepatic steatosis index (HSI) and fatty liver index (FLI), were calculated at baseline and follow-up visits. An external cohort from the UK Biobank was used to validate the correlation between proton density fat fraction magnetic resonance imaging scans of the liver and these surrogates.RESULTS:Compared with the control group, RDN significantly reduced HSI at 3 months (0.4±0.5 versus −1.3±0.3;P=0.009), 6 months (0.0±0.9 versus −2.6±0.5;P=0.027), and 12 months